Guanfacine (Intuniv, Tenex) Withdrawal: Rebound Blood Pressure and Tapering
Stopping guanfacine suddenly can push your blood pressure and heart rate above where they were before you ever started the drug. The FDA label for extended-release guanfacine tells prescribers to reduce the daily dose by no more than 1 mg every 3 to 7 days for exactly that reason. Guanfacine withdrawal is usually mild for people on low doses for short periods, and genuinely dangerous for a small number of people on higher doses, especially children and anyone also taking a stimulant.
This guide covers what happens in the body when guanfacine stops, how fast rebound shows up, why the immediate-release and extended-release forms behave differently, and what a safer taper looks like. The full guanfacine drug profile has the pharmacology and interaction details in one place.
Why guanfacine withdrawal causes rebound blood pressure
Guanfacine is a selective alpha-2A adrenergic agonist. It works by turning down the release of norepinephrine, the body's main "go" signal for alertness, heart rate, and vascular tone. In ADHD it strengthens signaling in the prefrontal cortex. In hypertension, which is what guanfacine was originally approved for as Tenex, it relaxes the blood vessels and slows the heart.
When you take guanfacine daily for months, the noradrenergic system adapts. Receptors and feedback loops reset around the assumption that guanfacine is present. Remove the drug quickly and that dampening disappears before the system has readjusted. Norepinephrine signaling overshoots, and blood pressure and pulse can climb past baseline.
Rebound hypertension is a blood pressure rise above your pre-treatment level after a blood-pressure-lowering drug is stopped, not simply a return to your old numbers. The FDA label for extended-release guanfacine reports that abrupt discontinuation has produced clinically significant and persistent rebound hypertension in postmarketing use, and that hypertensive encephalopathy, a medical emergency caused by dangerously high pressure affecting the brain, has been reported with both the extended-release and immediate-release forms.
Those severe cases are rare and clustered around specific conditions: higher doses, long duration, and concurrent stimulant use. Most people who taper guanfacine sensibly never come close to that. The label's own trial data in children and adolescents showed average increases of roughly 3 mmHg in blood pressure and 5 beats per minute in heart rate above original baseline after a tapered discontinuation, which is small.
Bottom line: guanfacine withdrawal is a noradrenergic rebound, and the speed of the reduction is what determines how sharp that rebound feels.
The guanfacine withdrawal timeline, day by day
Guanfacine withdrawal is fast compared to antidepressant withdrawal. The drug has a half-life of roughly 17 hours in adults and shorter in children, so it clears within a few days rather than weeks. That means symptoms arrive early and usually resolve early.
The label for immediate-release guanfacine notes that when rebound occurs it appears after 2 to 4 days, which is later than the rebound seen with clonidine, and that blood pressure in most cases drifts back to pretreatment levels within 2 to 4 days without lasting harm.
| Time after the last dose | What commonly happens | | | | First 24 hours | Trouble sleeping, restlessness, sometimes a headache as sedation lifts | | Days 2 to 4 | Peak window for blood pressure and heart rate rebound, headache, anxiety, irritability | | Days 5 to 10 | Return of the original ADHD symptoms, emotional reactivity, disrupted sleep | | Weeks 2 to 4 | Most autonomic symptoms have settled; what remains is usually the underlying condition, not withdrawal |
The most common complaints people describe after stopping guanfacine are headache, insomnia, anxiety, irritability, a racing or pounding heartbeat, and a stretch of days where emotional control feels thinner than usual. In children the visible sign is often a sharp return of hyperactivity and meltdowns that looks worse than the pre-medication baseline for a week or two.
Separating withdrawal from relapse matters here. Withdrawal symptoms show up within days of a dose change, peak, and then fade. Returning ADHD symptoms appear on a slower slope and stay level. If symptoms arrive within 72 hours of a reduction and improve over the following two weeks, the timing points to withdrawal.
Bottom line: guanfacine withdrawal peaks between day 2 and day 4 and mostly resolves inside 2 weeks, which is far shorter than SSRI or benzodiazepine withdrawal.
Guanfacine immediate-release (Tenex) versus extended-release (Intuniv): which is harder to stop?
Extended-release guanfacine is the harder one to stop safely, because it is used at higher total daily doses for longer periods and it carries the explicit rebound hypertension warning in its label. Immediate-release guanfacine produces a lower rebound rate, though it is dosed multiple times a day, so a single missed dose creates a bigger swing.
| Formulation | Typical use | Withdrawal profile | Best for |
|---|---|---|---|
| Immediate-release (Tenex, generic guanfacine) | Hypertension, off-label ADHD, tics | Rebound frequency described as low in the label; when it happens, it starts 2 to 4 days after stopping | People who want flexible dose sizes for a slow, fine-grained taper |
| Extended-release (Intuniv, generic guanfacine ER) | FDA-approved for ADHD in ages 6 to 17 | Explicit label warning for persistent rebound hypertension; label instructs reductions of no more than 1 mg every 3 to 7 days | People who need once-daily dosing and steady 24-hour coverage |
The practical difference is the tablet. Extended-release tablets must not be crushed, split, or chewed, because breaking the matrix dumps the full dose at once. That removes the easiest way to make small reductions and is why Intuniv tapers move in whole-milligram steps unless a prescriber compounds a liquid.
Immediate-release tablets can be split, which gives you smaller decrements. Some prescribers move a patient from extended-release to immediate-release specifically to gain that flexibility near the end of a taper. That is a formulation change of the same molecule, not a switch to a different drug, and it needs a prescriber's involvement because the two forms are not milligram-for-milligram equivalent.
Pros and cons run both ways. Extended-release is steadier day to day, but it locks you into coarse steps. Immediate-release allows a gentler landing, and its multiple daily doses mean more chances to forget one and trigger a mini-withdrawal.
Choose extended-release if consistency and once-daily simplicity matter more than taper precision. Choose immediate-release if you are actively coming off and want to reduce in smaller increments than 1 mg. Bottom line: the extended-release form carries the stronger rebound warning, and the immediate-release form gives you better tools to taper.
What the research actually shows about stopping guanfacine abruptly
The direct evidence is thinner than the warnings suggest, and being honest about that helps you plan. The main study is a 2007 Clinical Therapeutics trial by Kisicki and colleagues, a randomized comparison of abrupt cessation versus taper-down of extended-release guanfacine in 45 healthy adults aged 19 to 24 who had been titrated up to 4 mg over 16 days.
In that trial, abrupt cessation did not produce a clinically significant rise in systolic or diastolic blood pressure compared to tapering. Blood pressure actually fell slightly in both groups by the end of the study. So the catastrophic rebound picture is not what happens to most young, healthy people on a moderate dose for a short time.
One finding in the same study still argues for tapering. Treatment-emergent adverse events were reported by 93.3% of the abrupt-cessation group compared with 53.3% of the taper-down group (Kisicki et al., 2007), and headache was the most common complaint among those who stopped suddenly. Blood pressure was fine. People felt worse anyway.
The severe cases come from postmarketing reports, not trials, and they involve conditions the trial did not test: years of use instead of 16 days, higher doses, children rather than young adults, and stimulant co-prescription. The FDA specifically notes that children who cannot keep medication down during a stomach illness are at risk of an unplanned abrupt discontinuation.
Deprescribing.org, which develops evidence-based tapering guidance for clinicians, treats gradual reduction with monitoring as the default for any drug with autonomic effects, because the cost of going slowly is low and the cost of the rare bad outcome is high.
Bottom line: for most people abrupt guanfacine cessation is uncomfortable rather than dangerous, but tapering roughly halves the odds of feeling bad and removes the rare serious risk.
How to taper off guanfacine safely
The FDA label sets the outer boundary: reduce the total daily dose by no more than 1 mg every 3 to 7 days, and monitor blood pressure and pulse while reducing or after stopping, as stated in the DailyMed record for extended-release guanfacine. That is a maximum speed, not a target. Nothing stops a taper from being slower, and for people who have been on guanfacine for years, slower is usually easier.
The principle worth carrying over from other classes of psychiatric medication is proportional reduction. Each cut should be a percentage of the dose you are currently taking, not a fixed slice of the original dose. As the dose gets lower, the same 1 mg step removes a much larger share of the remaining drug effect, which is why the last stretch of a taper is often the roughest. The taper planner is built around that idea and works for any daily medication, and the tapering plan worksheet walks through the same reasoning on paper.
Buy a home blood pressure cuff before you start. This is the single most useful thing you can do for a guanfacine taper, because rebound is the risk that actually matters and it is invisible without a number. Take a reading at the same time each day, write it down, and hold the taper if readings climb meaningfully above your usual range.
Hold at a dose rather than pushing through a bad patch. If a reduction produces headaches, a pounding heart, or several nights of broken sleep, staying put until symptoms settle prevents the spiral where each cut lands on top of the last one. Tracking symptoms alongside blood pressure in a symptom journal makes the difference between a rough week and a real trend obvious.
Bottom line: cap your reductions at the label's speed, go slower if you have been on guanfacine a long time, monitor blood pressure daily, and hold rather than push.
"My child has been on Intuniv for 3 years and the doctor says to just stop it over the summer. Is that safe?"
A summer medication break is common practice in ADHD care, and stopping Intuniv without a taper is the part to push back on. Three years of daily use is well past the exposure tested in the 2007 abrupt-cessation trial, and long duration plus a higher maintenance dose is the profile behind the postmarketing rebound reports.
Ask for the taper the label already specifies rather than an argument about whether to stop. Reductions of no more than 1 mg every 3 to 7 days are printed in the prescribing information, so a prescriber has nothing to disagree with. For a child on 4 mg, that is a taper measured in weeks, not a single stop date.
Blood pressure and pulse checks matter more in children than adults, partly because kids do not report the early symptoms clearly and partly because of the vomiting problem. A stomach bug that keeps a child from holding down a dose creates the exact abrupt discontinuation the label warns about. Having a plan for sick days is worth asking about before it happens.
Watch for a rebound in behavior too. Many parents describe hyperactivity and emotional volatility that look worse than the original ADHD for a week or two after stopping. That overshoot settles, so judge whether the medication is still needed after about a month off, not during week one.
Bottom line: a summer break off Intuniv is reasonable, and it should be a taper over several weeks with blood pressure monitoring, not a stop date.
Guanfacine withdrawal when you also take a stimulant
Combining guanfacine with a stimulant such as Adderall or Vyvanse is a standard and well-supported ADHD regimen, and it changes the withdrawal math. Stimulants raise blood pressure and heart rate. Guanfacine lowers both. Remove the guanfacine quickly and the stimulant's cardiovascular effect is suddenly unopposed.
The FDA flags this directly: in the reported cases of rebound hypertension after abrupt discontinuation of high-dose guanfacine, concomitant stimulant use was also reported and may increase the hypertensive response. If you take both, the case for a slow taper with daily blood pressure readings is stronger, not weaker.
Change one drug at a time. Tapering guanfacine while also adjusting a stimulant dose makes it impossible to tell which change caused which symptom, and it stacks two cardiovascular effects in the same week. Finish one before starting the other.
NICE guideline NG87 on ADHD recommends that people on ADHD medication have their heart rate and blood pressure recorded at every dose change and every 6 months, which is the same monitoring a guanfacine taper needs. That recommendation gives you a concrete thing to request from a prescriber who is not used to being asked about tapering.
Bottom line: on a stimulant plus guanfacine, taper the guanfacine slowly, hold the stimulant steady, and track blood pressure at every step.
Frequently asked questions
Can I stop guanfacine cold turkey?
For a low dose taken for a few weeks, stopping abruptly is usually uncomfortable rather than dangerous, and the main complaint is headache and poor sleep. For anyone on a higher dose, on it for months or years, or taking a stimulant alongside it, cold turkey carries a real risk of rebound hypertension and the FDA label advises against it. Tapering costs weeks and removes the risk.
How long does guanfacine withdrawal last?
Most autonomic symptoms, meaning headache, racing heart, blood pressure elevation, and insomnia, peak 2 to 4 days after the last dose and settle within 1 to 2 weeks. What lingers beyond that is usually the return of the underlying ADHD or blood pressure condition rather than withdrawal.
Is Intuniv withdrawal different from Tenex withdrawal?
Intuniv, the extended-release form, carries the explicit rebound hypertension warning and the 1 mg per 3 to 7 days taper instruction, and its tablets cannot be split. Tenex and generic immediate-release guanfacine have a lower reported rebound frequency and can be split, which makes fine-grained reductions easier late in a taper.
What should I do if my blood pressure spikes after stopping guanfacine?
Contact your prescriber or an urgent care service the same day, and go to an emergency department if you have a severe headache, visual changes, confusion, or chest pain, since those are signs of a hypertensive emergency. Restarting the previous dose under medical supervision reliably reverses rebound, and a slower taper can start once things stabilize.
I forgot my guanfacine for 3 days while I was traveling and now I feel awful. What is happening?
Three missed days is functionally an abrupt discontinuation, which is why headache, anxiety, poor sleep, and a pounding heartbeat showed up. Do not double up to catch up. Contact your prescriber about restarting, since resuming a full dose after a gap can cause excessive sedation and low blood pressure, and check your blood pressure in the meantime.
Does guanfacine cause dependence or addiction?
No. Guanfacine is not a controlled substance and does not produce craving, euphoria, or dose escalation for effect. The rebound seen on stopping is physiological adaptation of the noradrenergic system, which is a different thing from addiction and is shared by many blood pressure medications.
Coming off guanfacine without guessing
Guanfacine withdrawal is one of the more manageable psychiatric medication tapers when it is done deliberately. The drug leaves the body quickly, symptoms peak within days, and the FDA has already published the maximum safe speed. The failure mode is almost always a sudden stop, whether that is a doctor saying to try a summer off, a lost prescription, or a stomach bug in a child.
If you are planning a taper, read the guanfacine drug profile for dosing and interaction details, and consider whether you need clinical support from a prescriber who understands deprescribing. Advocacy organizations covering both sides of this conversation are worth reading too, including CHADD for ADHD treatment guidance and Mad in America for critical coverage of psychiatric drug withdrawal.
taper.community is a free peer forum and resource library for people reducing or stopping psychiatric medication, built on the principle that dose reductions should be gradual and proportional to the dose you are currently taking. People tapering guanfacine, stimulants, and antidepressants compare notes in the forums every day, and reading how someone else handled the same step often answers a question faster than searching for it.
Medical disclaimer
This article is for information only and is not medical advice. Guanfacine affects blood pressure and heart rate, and stopping it without supervision can cause rebound hypertension. Do not change your dose or your child's dose without talking to a prescriber. If you experience a severe headache, chest pain, visual changes, or confusion after a dose reduction, seek emergency medical care.